-+ 0.00%
-+ 0.00%
-+ 0.00%

Orchestra BioMed Secures FDA Breakthrough Device Designation For AVIM Therapy, Targeting 7.7M U.S. Patients With Uncontrolled Hypertension

Benzinga·04/22/2025 11:08:15
Listen to the news

BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension who are the focus of the BACKBEAT global pivotal study Orchestra BioMed is currently enrolling in strategic collaboration with Medtronic, plc.